|
|||||
|
|
Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993–2016 |
|
| Authors: | Hidde L A Posthuma Josée M Zijlstra Otto Visser Pieternella J Lugtenburg Marie José Kersten Avinash G Dinmohamed |
| Institution: | 1. Department of Haematology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands;2. Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands;3. Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;4. Department of Haematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
Lymphoma and Myeloma Center Amsterdam (LYMMCARE), Amsterdam, The Netherlands |
| Abstract: | In this nationwide, population-based study, we assessed trends in primary treatment and survival among 687 patients with nodular lymphocyte-predominant Hodgkin lymphoma (75% males; median age, 40 years; and 74% stage-I/II disease) diagnosed in the Netherlands between 1993–2016. There were no noteworthy changes in the application of primary therapy over time among adult patients across the different disease stages and age groups. Survival among various subgroups of adult patients was largely comparable to the expected survival of the general population. A particularly encouraging finding was that young adult patients experienced virtually no excess mortality, as compared to the general population. |
| Keywords: | nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) cancer epidemiology population-based registry incidence survival |